Baraclude

Baraclude

entecavir

Manufacturer:

Bristol-Myers Squibb

Distributor:

DKSH
Concise Prescribing Info
Contents
Entecavir
Indications/Uses
Dosage/Direction for Use
Adult Nucleoside-naive 0.5 mg once daily. Lamivudine-refractory or w/ decompensated liver disease 1 mg once daily.
Administration
0.5-mg tab: May be taken with or without food. 1-mg tab: Should be taken on an empty stomach: Take >2 hr before or >2 hr after a meal.
Contraindications
Special Precautions
Lactic acidosis & severe hepatomegaly w/ steatosis. Monitor hepatic function after discontinuation of therapy. HIV/HBV co-infection. Renal impairment. Pregnancy & lactation. Childn <16 yr.
Adverse Reactions
Headache, fatigue, dizziness, nausea, diarrhea, dyspepsia.
Drug Interactions
Drugs that reduce renal function or compete for active tubular secretion may increase serum conc of either entecavir or co-administered drug.
MIMS Class
ATC Classification
J05AF10 - entecavir ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Presentation/Packing
Form
Baraclude FC tab 0.5 mg
Packing/Price
30's
Form
Baraclude FC tab 1 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in